Takeda, Brii Biosciences and Dr. Reddy s Laboratories made our news this week. (Google)
Takeda is buying its partner Maverick Therapeutics for its T-cell engager platform. The NIH has ended a clinical study testing Brii Biosciences anti-coronavirus antibody cocktail in hospitalized patients. Dr. Reddy s Laboratories is pulling a large volume of its generic Lipitor off U.S. pharmacy shelves due to impurities. And more.
Takeda exercised an option to buy out Maverick Therapeutics as part of a collaboration deal penned in early 2017. For up to $525 million upfront, Takeda’s getting full control of Maverick’s COBRA T-cell engager platform and the cancer pipeline built around it. These assets include lead candidate MVC-101, now known as TAK-186, which is in a phase 1/2 study in solid tumors that express EGFR.
Drug company issues recall for 47 bottles of blood pressure medicine over labeling error
Jacquelyn Martin/AP
Food and Drug Administration (FDA) signage is seen through a bus stop at the U.S. Department of Health and Human Services, Thursday, Aug. 2, 2018, in Silver Spring, Md., on the FDA grounds. (AP Photo/Jacquelyn Martin)
and last updated 2021-03-11 09:46:34-05
A California drug company has issued a voluntary recall of a medication used to treat high blood pressure and certain hormone issues due to a labeling error.
The nationwide recall issued by Bryant Ranch Prepack (BRP Pharmaceuticals) includes 47 bottles of spironolactone tablets â particularly bottles of 50 mg strength and 25 mg strength. According to the FDA, the 50 mg labels and 25 mg labels were incorrectly placed on the wrong bottle.
Feb 4, 2021 5:33pm
Enoxaparin sodium injection is used to treat and prevent deep vein thrombosis as well as heart attacks. (FDA)
Apotex recalled two batches of the anticoagulant enoxaparin after its contract manufacturer discovered it had packaged the drug in syringes with incorrect measurement markings.
Apotex pulled one 100-mg/mL batch of enoxaparin sodium injection and one 120-mg/0.8-mL batch after its CMO, Gland Pharma, received a customer complaint about the syringes.
Certain 120-mg/0.8-mL concentrations of the anticoagulant were packaged in syringes intended for 100-mg/mL concentrations, while some 100 mg/mL concentrations were put into in syringes marked for 150 mg/mL doses.
happened. but, of course, they want to avoid something happening. that is good news, right? they re trying to avoid that. and consumers caught this which i think is interesting. consumers called novartis and said what is going on here? i got there zanex in my bufferin. something like that. there are no zanex in the bufferin bottles, it was a joke. if you take these on a regular basis, maybe for migraines, what do do you? what do you is when you go to the store, you want to check those expiration dates. i want to tell you a story. for another drug recall, ways in the store. i went to go buy medicine for my daughter who had a fever. i found medicine there that had been recalled. it had been recalled and on the shelf. in a big chain store? yes. i brought an employee over and said i want to buy this but she said we forgot to take that off. don t rely on them to take it off the shelves. it s up to us. if you want to look at the